1
Jul
2018

Partner, Shelly Blatt Zak, represented Compugen, an Israeli clinical-stage drug discovery company, publicly traded on NASDAQ and TASE (CGEN), in a $21 million Registered Direct Offering of ordinary shares and warrants, to private US institutional investors.